Select Medical Holdings reports Q1 2026 results today with the borrow market flashing an unusual signal just ahead of the print.
Cost to borrow has jumped sharply in recent days. It has risen from around 0.17% in late April to 1.17% by April 29 — a near-seven-fold move in a week. That spike arrives against a backdrop of very loose availability: the lending pool remains almost entirely untapped, with borrow demand covering only a fraction of available supply. The contradiction is worth noting — the CTB move looks more like a technical squeeze on a thin slice of the borrow book than a broad surge in short-selling conviction. Short interest itself is modest at 2.2% of the free float, down roughly 2.4% on the week after a mid-April peak. Days to cover is 1.83, offering minimal squeeze fuel. The stock closed at $16.41 on April 30, essentially flat on the week and up less than 1% over the past month.
The analyst community turned more cautious earlier this year. RBC Capital downgraded SEM from Outperform to Sector Perform in early March, trimming its target from $19 to $16.50 — a notable pivot from a firm that had raised its target to $20 as recently as October 2025. Benchmark followed with its own downgrade to Hold. The consensus now sits at four Hold ratings and one Buy, with a mean target of $16.63, barely above the current price. The bull case centres on margin recovery in Critical Illness Recovery Hospitals as the company navigates CMS high-cost outlier thresholds, alongside IRF revenue growth of 15.7% driven by rising patient days and revenue per patient day. Bears point to the 500-basis-point drop in occupancy to 82% — partly a function of new hospital openings — and a 1.8% year-over-year decline in revenue per patient day, which signals pressure on the top line even as management guides toward occupancy above 85% for the rest of the year. Valuation offers limited cushion either way: the stock trades at roughly 12.6x earnings and 9.6x EV/EBITDA, both drifting lower over the past month.
Options positioning adds an unusual wrinkle. The put/call ratio of 5.41 is extraordinarily elevated in absolute terms, but it has actually eased slightly from its 20-day average of 5.49 — a z-score of -0.54 — suggesting options traders are no more defensive than they have been recently. The 52-week range on PCR runs from 0.01 to 5.95, and the current reading closer to the high end of that band reflects a structurally put-heavy options market for this name, not a fresh defensive shift ahead of results. The ORTEX short score of 30.3 has drifted lower over the past two weeks, consistent with short interest easing rather than building.
Ownership is concentrated and stable. Co-founder Robert Ortenzio holds 7.4% of shares, and the Ortenzio estate holds a further 3.7%, anchoring roughly 11% of the company in founding-family hands. BlackRock and Vanguard together hold another 25%. That ownership structure limits float and may partly explain why thin borrow demand can move CTB sharply without representing genuine short pressure.
The print will test whether the occupancy recovery management has promised is materialising — and whether CIRH margins are on the trajectory needed to justify even the modest re-rating embedded in the current price.
See the live data behind this article on ORTEX.
Open SEM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
